Evidence that oxytocin is a physiological component of LH regulation in non-pregnant women.

Evans JJ, Reid RA, Wakeman SA, Croft LB, Benny PS

Human reproduction (Oxford, England)1 Jul 2003Cited by 33 (Europe PMC)

PMID12832367DOI10.1093/humrep/deg291PepBankPUB-12832367

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Oxytocin.

01HumanNot a test of Oxytocin aloneRandomized controlled trialMechanism
In non-pregnant women, the oxytocin antagonist atosiban lowered the maximum LH concentration compared with saline in control cycles.
In plain wordsIn women, a drug that blocks oxytocin lowered the peak LH level compared with saline.
Peptide
Oxytocin
Outcome
DecreaseMaximum LH concentration
Study
n = 10
Comparator
Normal saline (control cycle)
Outcome group
Sex hormones and fertility · Endocrine and hormones
Measurements
Maximum LH
42.1 IU/l
atosiban cycles
Maximum LH
60.3 IU/l
control cycles
Source sentences
Summary
For treatment cycles, the maximum LH concentration was significantly less than that in control cycles (42.1 +/- 6.2 versus 60.3 +/- 8.3 IU/l respectively; P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Ten non-pregnant women participated in this study over two menstrual cycles.
Summary · context
In a control cycle, volunteers received normal saline; in a treatment cycle, volunteers received an oxytocin antagonist (atosiban).
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-1283236701
02HumanNot a test of Oxytocin aloneRandomized controlled trialMechanism
In non-pregnant women, the oxytocin antagonist atosiban did not significantly change maximum FSH concentration compared with saline.
In plain wordsIn women, a drug that blocks oxytocin did not significantly change peak FSH levels compared with saline.
Peptide
Oxytocin
Outcome
No significant changeMaximum FSH concentration
Study
n = 10
Comparator
Normal saline (control cycle)
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
Maximum FSH and estradiol concentrations
3 context sentences(design, population, supporting numbers)
Summary · context
were not significantly different between the two groups.
Summary · context
Ten non-pregnant women participated in this study over two menstrual cycles.
Summary · context
In a control cycle, volunteers received normal saline; in a treatment cycle, volunteers received an oxytocin antagonist (atosiban).
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-1283236702
03HumanNot a test of Oxytocin aloneRandomized controlled trialMechanism
In non-pregnant women, the oxytocin antagonist atosiban did not significantly change maximum estradiol concentration compared with saline.
In plain wordsIn women, a drug that blocks oxytocin did not significantly change peak estradiol levels compared with saline.
Peptide
Oxytocin
Outcome
No significant changeMaximum estradiol concentration
Study
n = 10
Comparator
Normal saline (control cycle)
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
Maximum FSH and estradiol concentrations were not significantly different between the two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten non-pregnant women participated in this study over two menstrual cycles.
Summary · context
In a control cycle, volunteers received normal saline; in a treatment cycle, volunteers received an oxytocin antagonist (atosiban).
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-1283236703

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 20:03 UTC
Study results updated
Version 1
9 Oct 2026, 02:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.